FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP
CIAILIVILIAI	OI OIIAIGES	III DEIIEI IOIAE	CAMINETOLIN

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				-	01 01	CCLIOIT	30(11)) or tile	III V C SUIII	int OO	ilipally Act	01 10-10							
1. Name and Address of Reporting Person* Hansen Gwenn				2. Issuer Name and Ticker or Trading Symbol Nurix Therapeutics, Inc. [NRIX]							(Che	ck all applic Directo	able)	g Pers	on(s) to Issu 10% Ow Other (s	ner			
(Last) (First) (Middle) C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205			3. Date of Earliest Transaction (Month/Day/Year) 11/30/2020										X below) below) Chief Scientific Officer						
(Street) SAN FRANCI			94158 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc Line)	' I							
(Oity)	(0		,											<u> </u>					
		Tab	le I - Non-	Deriva	tive	Secu	uritie	es Ac	quired	, Dis	posed o	of, or Be	nefi	icially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Execution Date,		3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1			() or 4 and	5. Amou Securitie Beneficia Owned F	es Form ally (D) of Following (I) (II		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)						
								Code	v	Amount	(A) or (D)		Price	Transact (Instr. 3	ction(s)			msu. 4)	
Common Stock 11/30/				2020				M	M 12,000 A		\$0.84	12,000			D				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any		4. Transaction Code (Instr. B)				6. Date Exercisable and Expiration Date (Month/Day/Year)		9	7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
				Co	ode V	,	(A) ((D)	Date Exercisa		Expiration Date	Title	or Nui of	mber ares					
Employee Stock Option (right to buy)	\$0.84	11/30/2020		N	М		1	12,000	(1)		02/10/2026	Common Stock	12	,000	\$0.00	31,333		D	

Explanation of Responses:

1. The option is fully vested.

Remarks:

/s/ Christine Ring, as Attorneyin-Fact for Gwenn Hansen

12/01/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.